Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

• Status: Unknown status
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Malnutrition is frequently seen in patients on chemotherapy suffering from gastric/colorectal cancer and may worsen the outcome. EPA, a sort of ω-3 PUFA, can modulate immune system. EPA also antagonizes metabolic and inflammatory changes induced by the tumor. This study is to test whether EPA, in combination with enteral nutrition, can improve nutritional/immunologic status, quality of life, and reduce chemotherapy related side effects of these patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion Criteria:

• The cases have undergone radical excision on gastric cancer or colorectal cancer.

• Without contraindication for chemotherapy.

• Eligible for postoperative adjuvant XELOX chemotherapy.

• Capable of taking in food or drug orally.

• Without severe absorption dysfunction

• Able and willing to give written, informed consent

Exclusion Criteria:

• Comorbidities: diseases of hematology or immunology system; hepatic or renal dysfunction; metabolic diseases.

• BMI>35kg/m2

• Life expectancy≤3mo

• The chemotherapy treatment is palliative.

• The patient has received radiotherapy or neoadjuvant chemotherapy prior to the operation.